Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma

NCT01501942 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide
DRUG: Buffered Saline

Sponsor

AIM Therapeutics Inc.